vs

Side-by-side financial comparison of IF Bancorp, Inc. (IROQ) and Arcus Biosciences, Inc. (RCUS). Click either name above to swap in a different company.

Arcus Biosciences, Inc. is the larger business by last-quarter revenue ($11.0M vs $7.3M, roughly 1.5× IF Bancorp, Inc.). IF Bancorp, Inc. runs the higher net margin — 18.1% vs -963.6%, a 981.8% gap on every dollar of revenue. On growth, IF Bancorp, Inc. posted the faster year-over-year revenue change (16.8% vs -52.2%). IF Bancorp, Inc. produced more free cash flow last quarter ($1.7M vs $-121.0M). Over the past eight quarters, IF Bancorp, Inc.'s revenue compounded faster (16.5% CAGR vs 4.9%).

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

IROQ vs RCUS — Head-to-Head

Bigger by revenue
RCUS
RCUS
1.5× larger
RCUS
$11.0M
$7.3M
IROQ
Growing faster (revenue YoY)
IROQ
IROQ
+69.0% gap
IROQ
16.8%
-52.2%
RCUS
Higher net margin
IROQ
IROQ
981.8% more per $
IROQ
18.1%
-963.6%
RCUS
More free cash flow
IROQ
IROQ
$122.7M more FCF
IROQ
$1.7M
$-121.0M
RCUS
Faster 2-yr revenue CAGR
IROQ
IROQ
Annualised
IROQ
16.5%
4.9%
RCUS

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
IROQ
IROQ
RCUS
RCUS
Revenue
$7.3M
$11.0M
Net Profit
$1.3M
$-106.0M
Gross Margin
Operating Margin
24.9%
-1036.4%
Net Margin
18.1%
-963.6%
Revenue YoY
16.8%
-52.2%
Net Profit YoY
8.9%
-12.8%
EPS (diluted)
$0.41
$-0.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IROQ
IROQ
RCUS
RCUS
Q4 25
$7.3M
$11.0M
Q3 25
$7.3M
$6.0M
Q2 25
$6.9M
$8.0M
Q1 25
$6.4M
$8.0M
Q4 24
$6.3M
$23.0M
Q3 24
$6.2M
$7.0M
Q2 24
$5.7M
$11.0M
Q1 24
$5.4M
$10.0M
Net Profit
IROQ
IROQ
RCUS
RCUS
Q4 25
$1.3M
$-106.0M
Q3 25
$1.4M
$-135.0M
Q2 25
$1.4M
$0
Q1 25
$1.0M
$-112.0M
Q4 24
$1.2M
$-94.0M
Q3 24
$633.0K
$-92.0M
Q2 24
$431.0K
$-93.0M
Q1 24
$708.0K
$-4.0M
Operating Margin
IROQ
IROQ
RCUS
RCUS
Q4 25
24.9%
-1036.4%
Q3 25
26.0%
-2366.7%
Q2 25
29.1%
-100.0%
Q1 25
21.7%
-1525.0%
Q4 24
26.8%
-447.8%
Q3 24
13.7%
-1500.0%
Q2 24
9.3%
-963.6%
Q1 24
17.6%
-160.0%
Net Margin
IROQ
IROQ
RCUS
RCUS
Q4 25
18.1%
-963.6%
Q3 25
19.0%
-2250.0%
Q2 25
21.0%
Q1 25
15.8%
-1400.0%
Q4 24
19.4%
-408.7%
Q3 24
10.2%
-1314.3%
Q2 24
7.6%
-845.5%
Q1 24
13.1%
-40.0%
EPS (diluted)
IROQ
IROQ
RCUS
RCUS
Q4 25
$0.41
$-0.88
Q3 25
$0.43
$-1.27
Q2 25
$0.48
$0.00
Q1 25
$0.31
$-1.14
Q4 24
$0.38
$-1.07
Q3 24
$0.20
$-1.00
Q2 24
$0.15
$-1.02
Q1 24
$0.22
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IROQ
IROQ
RCUS
RCUS
Cash + ST InvestmentsLiquidity on hand
$8.8M
$222.0M
Total DebtLower is stronger
$99.0M
Stockholders' EquityBook value
$87.4M
$631.0M
Total Assets
$830.4M
$1.1B
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IROQ
IROQ
RCUS
RCUS
Q4 25
$8.8M
$222.0M
Q3 25
$8.0M
$238.0M
Q2 25
$20.1M
$248.0M
Q1 25
$8.9M
$192.0M
Q4 24
$5.9M
$150.0M
Q3 24
$7.8M
$201.0M
Q2 24
$9.6M
$156.0M
Q1 24
$16.1M
$185.0M
Total Debt
IROQ
IROQ
RCUS
RCUS
Q4 25
$99.0M
Q3 25
$98.0M
Q2 25
$97.0M
Q1 25
$48.0M
Q4 24
$48.0M
Q3 24
$47.0M
Q2 24
Q1 24
Stockholders' Equity
IROQ
IROQ
RCUS
RCUS
Q4 25
$87.4M
$631.0M
Q3 25
$84.5M
$436.0M
Q2 25
$81.8M
$549.0M
Q1 25
$78.9M
$531.0M
Q4 24
$75.9M
$485.0M
Q3 24
$78.8M
$565.0M
Q2 24
$73.9M
$635.0M
Q1 24
$72.4M
$707.0M
Total Assets
IROQ
IROQ
RCUS
RCUS
Q4 25
$830.4M
$1.1B
Q3 25
$862.3M
$974.0M
Q2 25
$887.7M
$1.1B
Q1 25
$879.1M
$1.2B
Q4 24
$885.1M
$1.1B
Q3 24
$893.4M
$1.3B
Q2 24
$887.7M
$1.2B
Q1 24
$905.0M
$1.3B
Debt / Equity
IROQ
IROQ
RCUS
RCUS
Q4 25
0.16×
Q3 25
0.22×
Q2 25
0.18×
Q1 25
0.09×
Q4 24
0.10×
Q3 24
0.08×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IROQ
IROQ
RCUS
RCUS
Operating Cash FlowLast quarter
$1.8M
$-120.0M
Free Cash FlowOCF − Capex
$1.7M
$-121.0M
FCF MarginFCF / Revenue
23.7%
-1100.0%
Capex IntensityCapex / Revenue
0.9%
9.1%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$9.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IROQ
IROQ
RCUS
RCUS
Q4 25
$1.8M
$-120.0M
Q3 25
$-539.0K
$-97.0M
Q2 25
$6.8M
$-133.0M
Q1 25
$1.8M
$-132.0M
Q4 24
$-155.0K
$-100.0M
Q3 24
$2.2M
$26.0M
Q2 24
$2.3M
$-94.0M
Q1 24
$19.0K
$-2.0M
Free Cash Flow
IROQ
IROQ
RCUS
RCUS
Q4 25
$1.7M
$-121.0M
Q3 25
$-582.0K
Q2 25
$6.5M
Q1 25
$1.8M
$-133.0M
Q4 24
$-226.0K
$-101.0M
Q3 24
$2.1M
$25.0M
Q2 24
$2.0M
Q1 24
$-67.0K
$-6.0M
FCF Margin
IROQ
IROQ
RCUS
RCUS
Q4 25
23.7%
-1100.0%
Q3 25
-7.9%
Q2 25
95.1%
Q1 25
28.2%
-1662.5%
Q4 24
-3.6%
-439.1%
Q3 24
33.6%
357.1%
Q2 24
35.7%
Q1 24
-1.2%
-60.0%
Capex Intensity
IROQ
IROQ
RCUS
RCUS
Q4 25
0.9%
9.1%
Q3 25
0.6%
0.0%
Q2 25
3.5%
0.0%
Q1 25
0.4%
12.5%
Q4 24
1.1%
4.3%
Q3 24
1.2%
14.3%
Q2 24
4.3%
0.0%
Q1 24
1.6%
40.0%
Cash Conversion
IROQ
IROQ
RCUS
RCUS
Q4 25
1.36×
Q3 25
-0.39×
Q2 25
4.69×
Q1 25
1.81×
Q4 24
-0.13×
Q3 24
3.42×
Q2 24
5.30×
Q1 24
0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IROQ
IROQ

Segment breakdown not available.

RCUS
RCUS

Other$5.0M45%
Other Collaboration Revenue$4.0M36%
Access Rights And Option Continuation Periods$2.0M18%

Related Comparisons